Key Points The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products. 10 stocks we like better than Glaukos › Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by nearly 14% that trading session, thanks almost entirely to a solid quarterly earnings report. The stock's pe ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Commission file number: 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

Key Takeaways GKOS posted Q3 loss of 16 cents per share, beating estimates, with revenue up 38% to $133.5M.GKOS' Glaucoma sales surged 45%, and gross margin rose to 84% from 82% a year ago.GKOS raised 2025 sales outlook to $490-$495M, citing strong iDose TR adoption and FDA-approved Epioxa launch.Glaukos Corporation (GKOS) reported third-quarter 2025 adjusted loss of 16 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 27 cents. The figure also improved from the year-ago qua ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Glaukos (NYSE:GKOS) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Company ParticipantsChris Lewis - VP of Investor Relations and Corporate AffairsJoe Gilliam - President and COOTom Burns - Chairman and CEOConference Call ParticipantsJoanne Wuensch - Managing Director and Healthcare Research AnalystRyan Zimmerman - Managing Director and Medical Technology AnalystDavid Roman - AnalystMason Carrico - Research AnalystRichard Newitter - Managing Director and Senior Equity Research AnalystDavid Saxon - Senio ...

Glaukos (NYSE:GKOS) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Company ParticipantsChris Lewis - VP of Investor Relations and Corporate AffairsJoe Gilliam - President and COOTom Burns - Chairman and CEOConference Call ParticipantsJoanne Wuensch - Managing Director and Healthcare Research AnalystRyan Zimmerman - Managing Director and Medical Technology AnalystDavid Roman - AnalystMason Carrico - Research AnalystRichard Newitter - Managing Director and Senior Equity Research AnalystDavid Saxon - Senio ...

Glaukos (NYSE:GKOS) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Speaker3Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today. At this time, I would like to welcome you to the Glaukos Corporation's Third Quarter 2025 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market close today, are available at www.glaukos.com. All lines have been placed on mute to prevent any b ...

Exhibit 99.2 OCTOBER 29, 2025 GLAUKOS CORPORATION (NYSE: GKOS) THIRD QUARTER 2025 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation's recent financial and operational performance and general business outlook. Please see "Forward-Looking Statements" and "Statement Regarding Use of Non- GAAP Financial Measures" in the "Additional Information" section of this ...

主要升级 - Wells Fargo将Glaukos评级从等权重上调至超配，目标价从92美元上调至120美元，认为其Epioxa是未被充分认识的重要增长动力 [2] - RBC Capital将Honeywell评级从行业一致上调至跑赢行业，目标价从235美元上调至253美元，公司第三季度业绩稳健，标志着其进入拆分催化剂密集阶段 [3] - Truist将Booking Holdings评级从持有上调至买入，目标价从5,630美元上调至5,750美元，依据是亚洲旅游业的长期前景、稳定的全球GDP增长以及更具吸引力的股票估值 [3] - JPMorgan将Five Below评级从中性上调至超配，目标价从154美元上调至186美元，预计公司在第三季度报告前将实现至少低双位数的多年盈利增长 [4] - Guggenheim将Microsoft评级从中性上调至买入，目标价为586美元，认为公司与其他超大规模供应商一样是人工智能发展的受益者 [5] 主要降级 - Keefe Bruyette将Berkshire Hathaway评级从市场一致下调至弱于行业，目标价从735,000美元大幅下调至7,000美元，认为Geico的承保利润率见顶、财产巨灾再保险费率下降、短期利率走低、铁路业务面临关税压力以及替代能源税收抵免政策可能减弱等因素将导致其未来12个月表现不佳 [5] - Morgan Stanley将Harley-Davidson评级从等权重下调至减持，目标价从27美元下调至25美元，存在10%的下行潜力，公司下调了预期并认为市场共识预期将进一步下降 [5] - RBC Capital将Roper Technologies评级从跑赢行业下调至行业一致，目标价从644美元下调至539美元，鉴于投资者偏好风险偏好型交易，认为该股相对上行空间有限 [5] - Jefferies将Keysight Technologies评级从买入下调至持有，目标价从181美元微调至180美元，公司看好其中低个位数的有机增长潜力，但认为当前估值已充分反映此预期 [5] - Williams Trading将Wolverine World Wide评级从买入下调至持有，目标价从30美元下调至27美元，预计其Saucony品牌的同比销售增长将在2026年初减速至低个位数 [5]

The U.S. Food and Drug Administration has approved a new eye therapy from Glaukos Corp , giving patients a less painful and more convenient option to treat a progressive condition that can severely af... ...